Published in Lancet Neurol on April 19, 2013
Restless legs syndrome and cerebrovascular disease. Lancet Neurol (2013) 1.07
Executive dysfunction in Parkinson's disease and timing deficits. Front Integr Neurosci (2013) 0.89
Mouse models of neurodevelopmental disease of the basal ganglia and associated circuits. Curr Top Dev Biol (2014) 0.81
Deep brain stimulation in Parkinson's disease. Transl Neurodegener (2013) 0.81
Delayed Hemichorea Following Temporal-Occipital Lobe Infarction. Tremor Other Hyperkinet Mov (N Y) (2016) 0.80
Post-stroke dyskinesias. Neuropsychiatr Dis Treat (2016) 0.79
Association of Sleep Disordered Breathing with Wake-Up Acute Ischemic Stroke: A Full Polysomnographic Study. J Clin Sleep Med (2016) 0.77
Involuntary movement in pediatric moyamoya disease patients: consideration of pathogenetic mechanism using neuroimaging studies. Childs Nerv Syst (2013) 0.76
Cerebral Venous Thrombosis in the Superior Sagittal Sinus as a Rare Cause of a Paroxysmal Kinetic Tremor. Case Rep Neurol (2017) 0.75
Movement Disorders Following Cerebrovascular Lesion in the Basal Ganglia Circuit. J Mov Disord (2016) 0.75
Hemichorea-hemiballismus caused by postoperative hyperperfusion after clipping of a giant unruptured middle cerebral artery aneurysm. Surg Neurol Int (2015) 0.75
Focal (123)I-FP-CIT SPECT Abnormality in Midbrain Vascular Parkinsonism. Case Rep Neurol Med (2015) 0.75
Supplementary Motor Complex and Disturbed Motor Control - a Retrospective Clinical and Lesion Analysis of Patients after Anterior Cerebral Artery Stroke. Front Neurol (2015) 0.75
Abnormal movements in critical care patients with brain injury: a diagnostic approach. Crit Care (2016) 0.75
Restless legs syndrome and cerebrovascular disease - authors' reply. Lancet Neurol (2013) 0.75
Can a stroke present with flexor spasms? A highly rare experience. Ger Med Sci (2014) 0.75
Movement disorders of probable infectious origin. Ann Indian Acad Neurol (2014) 0.75
Movement Disorders Following Cerebrovascular Lesions: Etiology, Treatment Options and Prognosis. J Mov Disord (2016) 0.75
Deterioration of palatal myoclonus after acute thalamic hemorrhage. Transl Neurosci (2015) 0.75
Successful treatment with intravenous recombinant tissue plasminogen activator in an acute stroke patient presenting with hemiballism. Funct Neurol (2015) 0.75
Punding following posterior cerebral artery infarction: a case report and literature review. Neuropsychiatr Dis Treat (2017) 0.75
Post stroke hemi-dystonia in children: a neglected area of research. Mol Cell Pediatr (2015) 0.75
Movement Disorders Following Cerebrovascular Lesions in Cerebellar Circuits. J Mov Disord (2016) 0.75
MRI measurements of brainstem structures in patients with vascular parkinsonism, progressive supranuclear palsy, and Parkinson's disease. Neurol Sci (2017) 0.75
Pseudobulbar paralysis in the Renaissance: Cosimo I de' Medici case. Neurol Sci (2014) 0.75
Limb-shaking TIA: on the borders of evidence-based medicine. Intern Emerg Med (2017) 0.75
Asterixis in the leg induced by anterior cerebral artery infarction. Neurol Sci (2016) 0.75
Chorea-ballism associated with ketotic hyperglycemia. Neurol Sci (2014) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord (2006) 2.72
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol (2012) 2.50
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology (2013) 2.45
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord (2007) 2.34
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain (2008) 2.34
Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet (2002) 2.27
Camptocormia: pathogenesis, classification, and response to therapy. Neurology (2005) 2.26
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord (2011) 2.16
Are Parkinson disease patients protected from some but not all cancers? Neurology (2007) 2.12
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg (2006) 2.02
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Genetics of essential tremor. Brain (2007) 1.89
Update on blepharospasm: report from the BEBRF International Workshop. Neurology (2008) 1.87
Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx (2006) 1.82
Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord (2006) 1.82
Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord (2010) 1.76
Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist (2008) 1.74
Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci (2009) 1.73
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Premutation alleles associated with Parkinson disease and essential tremor. JAMA (2004) 1.65
Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun (2005) 1.64
Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci (2004) 1.62
Migraine headache in patients with Tourette syndrome. Arch Neurol (2003) 1.61
Minocycline in Huntington's disease: a pilot study. Mov Disord (2004) 1.59
Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat (2010) 1.57
Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol (2009) 1.56
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord (2008) 1.56
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord (2005) 1.54
Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol (2005) 1.54
Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol (2003) 1.53
Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord (2010) 1.52
Secondary tics and tourettism. Rev Bras Psiquiatr (2005) 1.47
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci (2011) 1.46
Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis (2008) 1.43
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics (2010) 1.37
The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry (2013) 1.36
Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord (2003) 1.35
Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin (2004) 1.33
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord (2007) 1.32
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord (2010) 1.31
Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals (2011) 1.30
Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol (2006) 1.29
Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain (2006) 1.29
Nurr1 in Parkinson's disease and related disorders. J Comp Neurol (2006) 1.27
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon (2013) 1.27
Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol (2002) 1.26
Runner's dystonia. J Neurol Sci (2006) 1.24
Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord (2004) 1.24
Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord (2006) 1.23
Iron dysregulation in movement disorders. Neurobiol Dis (2012) 1.22
A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A (2006) 1.20
Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA). Curr Neuropharmacol (2013) 1.20
Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm (Vienna) (2013) 1.20
An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) (2013) 1.20
Essential tremor quantification during activities of daily living. Parkinsonism Relat Disord (2011) 1.18
Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord (2007) 1.18
Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology (2002) 1.18
Reliability of a new scale for essential tremor. Mov Disord (2012) 1.17
Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord (2007) 1.17
Secondary paroxysmal dyskinesias. Mov Disord (2002) 1.17
Correlation between Kinesia system assessments and clinical tremor scores in patients with essential tremor. Mov Disord (2010) 1.17
Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother (2006) 1.16
Movement disorders in autoimmune diseases. Mov Disord (2012) 1.16
Safety of MRI in patients with implanted deep brain stimulation devices. Neuroimage (2009) 1.16
The clinical features of psychogenic movement disorders resembling tics. J Neurol Neurosurg Psychiatry (2013) 1.15
Preclinical biomarkers of Parkinson disease. Arch Neurol (2011) 1.14
Head injury, α-synuclein Rep1, and Parkinson's disease. Ann Neurol (2012) 1.14
The genetics of Tourette syndrome. Nat Rev Neurol (2012) 1.13
Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol (2008) 1.12
Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology (2014) 1.11
Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci (2008) 1.10
Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol (2005) 1.10
Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol (2002) 1.10
Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord (2010) 1.09
Pain in Parkinson's disease. Mov Disord (2011) 1.09
Symptomatic treatment of Huntington disease. Neurotherapeutics (2008) 1.08
Amplitude fluctuations in essential tremor. Parkinsonism Relat Disord (2012) 1.08
A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol (2008) 1.07
Bilateral globus pallidus internus deep brain stimulation after bilateral pallidotomy in a patient with generalized early-onset primary dystonia. Mov Disord (2013) 1.07
Malignant Tourette syndrome. Mov Disord (2007) 1.07
The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord (2011) 1.06